High Dimensional Imaging Mass Cytometry Panel to Visualize the Tumor Immune Microenvironment Contexture.
biomarkers
imaging mass cytometry
immune therapies
panel design
tumor immune microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
02
2021
accepted:
29
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
15
10
2021
Statut:
epublish
Résumé
The integrative analysis of tumor immune microenvironment (TiME) components, their interactions and their microanatomical distribution is mandatory to better understand tumor progression. Imaging Mass Cytometry (IMC) is a high dimensional tissue imaging system which allows the comprehensive and multiparametric
Identifiants
pubmed: 33936105
doi: 10.3389/fimmu.2021.666233
pmc: PMC8085494
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
666233Informations de copyright
Copyright © 2021 Elaldi, Hemon, Petti, Cosson, Desrues, Sudaka, Poissonnet, Van Obberghen-Schilling, Pers, Braud, Anjuère and Meghraoui-Kheddar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cytometry A. 2016 Mar;89(3):292-300
pubmed: 26355391
Clin Cancer Res. 2021 Apr 1;27(7):1987-1996
pubmed: 33504554
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Nat Methods. 2012 Feb 28;9(3):245-53
pubmed: 22373911
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Cytometry A. 2020 Aug;97(8):782-799
pubmed: 32602650
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Nature. 2020 Feb;578(7796):615-620
pubmed: 31959985
Front Immunol. 2019 Nov 14;10:2657
pubmed: 31798587
Front Immunol. 2020 Jul 16;11:1466
pubmed: 32765508
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Discov. 2020 Mar;10(3):406-421
pubmed: 31857391
IEEE Trans Vis Comput Graph. 2021 Jan;27(1):98-110
pubmed: 31369380
Oral Oncol. 2015 Jan;51(1):16-23
pubmed: 25456006
J Invest Dermatol. 2020 Sep;140(9):1723-1732
pubmed: 32061658
Cell Rep. 2020 Apr 21;31(3):107523
pubmed: 32320656
Ann Transl Med. 2020 Nov;8(22):1513
pubmed: 33313258
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 30906572
Cell Rep. 2019 Oct 1;29(1):202-211.e6
pubmed: 31577949
Cancer Cell. 2017 Mar 13;31(3):342-354
pubmed: 28292437
Cancer Immunol Res. 2020 Sep;8(9):1122-1138
pubmed: 32665262
Cell. 2020 Sep 3;182(5):1341-1359.e19
pubmed: 32763154
Lancet Oncol. 2020 Feb;21(2):294-305
pubmed: 31952975
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Front Immunol. 2019 Jul 09;10:1571
pubmed: 31354723
Front Immunol. 2019 Oct 29;10:2534
pubmed: 31736961
Nat Rev Clin Oncol. 2021 Apr;18(4):244-256
pubmed: 33277626
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
J Am Acad Dermatol. 2013 Jun;68(6):957-66
pubmed: 23375456
Nat Methods. 2017 Sep;14(9):873-876
pubmed: 28783155